In addition to mutations in the CEBPA gene, which were detected in approximately in 6−15% of de novo AML and in 15−18% of AML with normal karyotypes (11), silencing of CEBPA expression due to promoter hypermethylation was found in a small subset of AML patients with myeloid/T-lymphoid features (12). This evidence concerns the gene CEBPA and acute myeloid leukemia.